Macomics Alzheimer's disease program (lipid-induced microglia neuroinflammation)

Macomics is developing an undisclosed therapeutic program aimed at treating Alzheimer's disease by targeting lipid-induced microglia neuroinflammation. Microglia, the resident macrophages of the central nervous system, play a critical role in neurodegenerative pathology. This program focuses on modulating or inhibiting the inflammatory response triggered by lipid accumulation in microglia, a process increasingly recognized as a driver of neurodegeneration in Alzheimer's. The development is currently in the discovery phase, leveraging Macomics' proprietary macrophage biology platform. The company utilizes a modality-agnostic approach, potentially employing either monoclonal antibodies or small molecules to achieve therapeutic effects.